EMBL Ventures

EMBL Ventures is the corporate venture capital arm of the European Molecular Biology Laboratory (EMBL), dedicated to investing in early-stage life science companies throughout Europe. The firm focuses on creating significant commercial opportunities based on new therapeutic treatment modalities, next-generation enabling technology platforms, and innovations in diagnostics and medical devices. EMBL Ventures manages three funds totaling €120 million on behalf of major European private and institutional investors, typically investing between €5 million and €40 million as lead or co-lead investors.

The firm's investment strategy emphasizes a close relationship with EMBL and its technology transfer organization, EMBLEM, providing unique access to a vast network of scientific expertise and resources. This collaboration enables EMBL Ventures to identify and support disruptive technologies, fostering the growth of companies that can make a substantial impact in the life sciences sector. EMBL Ventures' team combines significant scientific and industry-related networks with a strong investment track record, offering hands-on support to portfolio companies and facilitating collaborations, licensing agreements, mergers and acquisitions, and initial public offerings.

With a focus on sectors such as med-tech, bio-tech, and health-tech, EMBL Ventures has a proven track record of successful investments, including the acquisition of portfolio company ViraTherapeutics by Boehringer Ingelheim in a transaction valued at €210 million. This acquisition highlights the firm's ability to identify and nurture high-potential companies in the life sciences domain, contributing to advancements in healthcare and biotechnology across Europe.